PRAK-03202 - Akers Biosci, Premas Biotech
PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2. (PubMed, Heliyon) - Oct 12, 2021 - "Peripheral blood mononuclear cells from convalescent patients showed lymphocyte proliferation and elevated interferon levels suggestive of epitope conservation and induction of T helper 1-biased cellular immune response when exposed to PRAK-03202. These data support further clinical development and testing of PRAK-03202 for use in humans." 
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/34632131
 
Oct 12, 2021
 
Prev Next